Introduction
Experimental autoimmune uveoretinitis (EAU) is an autoimmune disease that serves as a model for several human ocular diseases that may lead to blindness. 1, 2 It is due to a CD4 þ T-cell response leading to irreversible destruction of the visual cells located in the retina. 3 EAU is systemically induced by footpad injection of purified retinal autoantigens in adjuvants, but the expression of the pathology is restricted to the eye. Th1 cells specific for retinal autoantigens migrate from the peripheral lymphoid system to the target retinal tissue and, after homing in the eye and recruitment of other inflammatory cells, induce alterations of the target ocular structures, that is, the retinal photoreceptors. The pathogenesis of EAU has been related to an elevation of inflammatory Th1 cytokines in uveitic eyes, whereas Th2 cytokines increase at later stages of EAU. [4] [5] [6] [7] In human eye diseases, corticosteroids and other immunosuppressive agents are very commonly used in the treatment of severe posterior segment intraocular inflammation (uveitis) either by systemic or local administration. However, such treatments, even though efficient, can induce serious complications such as effects on endocrine function and neoplastic transformation when administered systemically. Even local treatment, for example, periocular corticosteroid injections, may lead to cataract or elevation of intraocular pressure, aggravating the loss of vision due to the uveitis-related lesions. These drawbacks explain the increasing interest in local therapy using new molecules, devoid of the side effects of the corticosteroids but as efficient in reducing ocular inflammation and preventing tissue destruction. Recently, relevant research has focused on the possibility of treating autoimmune diseases with molecules that downregulate the antigen presentation such as the regulatory cytokine IL-10 or molecules blocking costimulatory signalization such as CTLA4. Interestingly, immune privilege of the eye has been attributed to a number of factors including IL-10 production. In addition, systemic injections of IL-10 6 and systemic administration of antibodies to B7.1 and B7.2 8 limit expression of the experimental uveitis, but, due to a short half-life, daily injections of these regulatory molecules have been needed to obtain this protection.
The use of gene delivery to treat ocular disease is particularly attractive due to accessibility and compartmentalization of the ocular tissues. Gene transfer technology, in addition to the possibility of replacing a defective gene product, also offers the opportunity to provide a temporary protein expression in a given tissue. In this sense, adenovirus is particularly well adapted, the time of expression of the transferred gene being dependent on the natural elimination of the virus and infected cells by the elicited immune response. We have previously shown that a single systemic injection of vIL-10-expressing adenovirus (Ad-vIL-10) significantly decreased the severity of ocular inflammation and tissue destruction in mouse and rat models of uveitis. 9 In that study, the viral IL-10 was preferred over cellular IL-10 as it exhibits only the immunosuppressive properties of this cytokine (reviewed in Moore et al 10 ) and therapeutic efficacy has previously been shown in transplantation 11 including corneal grafting, 12 and in other autoimmune diseases. [13] [14] [15] [16] With regard to an organ-restricted autoimmune disease, such as many forms of uveitis, there is great interest in local gene delivery and we have shown in our previous work that subconjunctival administration of Ad-vIL-10 inhibited EAU. 9 In the present study, we have investigated the feasibility of a direct intraocular expression of vIL-10 delivered by adenovirus vector either by direct free AdvIL-10 injection or by injection of rat retinal cells infected ex vivo, in the rat Lewis model of uveitis. Using GFPexpressing adenovirus (Ad-GFP), we first defined the parameters of the intraocular transgene expression. We then assessed the protective effects of vIL-10 expression during EAU, following intraocular injection into the eye of retinal cells infected ex vivo with recombinant adenovirus. Finally, we investigated the potential of this therapeutic approach to inhibit EAU, targeting the eye to express another potent immunosuppressive factor, CTLA4, using genetically modified cells.
Results

In vitro transgene expression by adenovirus-infected retinal Mü ller glial (RMG) cells
To control their susceptibility to adenoviral infection, RMG cells were infected with increasing quantities of Ad-GFP (0-200 pfu/cell) and analyzed for GFP fluorescence by flow cytometry after 24 or 48 h of culture. GFP expression was detected from a low pfu/cell ratio (5 pfu/cell), increasing in a dose-dependent manner up to 50 pfu/cell and then progressively reaching a plateau with higher infective doses (more than 90% at 200 pfu/ cell) (Figure 1a ). Under these conditions, no signs of cytotoxicity were observed under microscopic examination, the viability of cells being altered at a higher ratio of viral pfu/cell (500 pfu/cell).
After infection with vIL-10-expressing adenovirus (Ad-vIL-10), RMG cells (RMG-vIL-10) produced large quantities of cytokine, detectable in cellular supernatants as early as day 1, and increasing from day 1 to day 6 depending on the pfu/cell ratio (Figure 1b) . From different in vitro experiments, it was estimated that vIL-10 production ranged from to 50 to 200 ng/24 h/3 Â 10 5 cells.
In vivo transgene expression after Ad-GFP and RMG-GFP injection into the eye Free Ad-GFP was injected into the vitreous body. This intravitreal injection led to efficient GFP expression in both anterior (endothelium of the cornea, trabecular meshwork and iris/cilary body epithelium) (data not shown) and posterior segments of the eye (fluorescence was present in numerous GFAP þ Mü ller cells from the basal end feet to the apical region of the outer nuclear layer) at day 3 ( Figure 2aA ). A marked inflammatory reaction characterized by the presence of ED1 þ cells (mainly macrophages) was also observed in the retina at this time (Figure 2aB ). This gene expression lasted for only a limited period of time (no more than 7 days) and, as a major drawback, involved the infection of resident cells of the retina, together with marked inflammation.
In a second series of experiments, RMG cells were infected ex vivo with Ad-GPF (at a ratio of 200 pfu/cell) and, the following day injected into the vitreous of both eyes. GFP fluorescence was analyzed at days 3, 7 and 13. Numerous RMG-GFP cells were detected at days 3 and 7 ( Figure 2bA and B, respectively) and some were still detectable at day 13 (data not shown). These injected cells were most often located in the vitreous close to the lens and facing the papilla of the optic nerve, probably due to the passive movements of these cells within the vitreous of the rat. No reporter gene expression was seen in the ocular tissues of the recipient (Figure 2bC ) at any time postinjection. Some inflammatory cell infiltration (ED1 þ cells) was detected in the ocular tissues at day 7 postinjection, surrounding the RMG-GFP-injected cells and infiltrating the host retina (Figure 2bD ). However, no deleterious effect, including alterations of the retina, was noted up to day 13.
Using RT-PCR analysis, similar kinetics of transgene expression was observed after intravitreal injection of vIL-10-expressing RMG. As shown by Figure 3 , vIL-10 mRNA were present at high level in the whole eyes at days 3 and 7, decreasing progressively through day 13 and were undetectable by day 20. A mean value of 25 ng/ml of vIL-10 (mean of five animals) was determined by ELISA in the aqueous humor and the vitreous body 4 days after injection of RMG-vIL-10, whereas no vIL-10 was detected in the sera of the same animals.
Phenotypic analysis of adenovirus-infected RMG cells
It was previously shown that retinal Mü ller cells undergo phenotypic changes in culture. In particular, these cells may de-differentiate and acquire the ability to generate Intraocular gene therapy for ocular inflammation C Verwaerde et al tractional forces, enabling them to participate in the formation of contractile scars. [17] [18] [19] This activity is simultaneous with the expression of a smooth muscle actin (aSMA) and the loss of some markers such as glial fibrillary acidic protein (GFAP) after 2 weeks culture.
We thus investigated the expression of different cell markers on adenovirus-infected RMG cells before, and at different time points after injection into the vitreous. In vitro RMG cells (passage 2-3, approximately 4 days of culture subsequent to the last passage) appeared slightly positive for the markers CRALBP and GFAP, highly positive for the marker, vimentin, and negative for the marker aSMA (data not shown). No difference was observed between control cells and cells infected with Ad-vIL-10 or Ad-vIL-10mut. In vivo analysis was performed at 3, 7 and 13 days after intraocular injection of RMG cells infected with Ad-vIL-10. No a-SMA was detected in the injected RMG cells nor in the host retina at any time point (data not shown).
In conclusion, under our defined experimental conditions, phenotypic changes of injected RMG and host RMG appeared to be very limited excluding the possibility of development of contractile activity.
Effect on EAU of intravitreal vIL-10 gene transfer using free adenovirus or ex vivo vIL-10-transfected retinal cells
In view of the efficiency of transgene expression after injecting adenovirus directly into the vitreous cavity, we assessed the efficacy of the vIL-10 in prevention of EAU. At day 0 of immunization, rats were injected intravitreally in one eye with either Ad-vIL-10 or the corresponding nonexpressing control adenovirus, Ad-vIL-10mut or saline. For each group, the fellow eye was not injected. As shown in Figure 4 , no difference in disease intensity was detected at day 21 in the eyes injected with saline or Ad-vIL-10mut compared to the fellow noninjected eye. In the eyes injected with Ad-vIL-10, the treatment reduced EAU pathology by 40% compared to the noninjected eye and by 33% when compared to the eyes injected with Ad-vIL-10mut. Given the long duration of gene expression and the sparing of host retina from viral infection when ex vivo transfected cells are used as opposed to free virus, we subsequently injected RMG-vIL-10 into the vitreous. Both eyes of rats were injected on the same day as SAg immunization. Cells infected with the mutated control Ad-vIL-10mut (RMG-mut) were used as controls for this work. Analysis of the pathology was performed between day 16 and 21 depending on the experiment (day 21 for Experiments 1 and 3, day 16 for Experiment 2). Treatment of rats with RMG-vIL-10 led to a significant decrease of EAU severity when compared to RMG-mutinjected animals (29, 27 and 27% reduction, respectively, for Experiments 1, 2 and 3) (Figures 5a and b and 6). EAU score obtained for the two eyes of each animal were presented separately to reflect possible variability due to the direct inoculation of the cells into the vitreous. Compared to controls, the eyes of which showed complete destruction of the photoreceptor cell layer and part of the bipolar cell layer, limited alteration of the retina with partial preservation of the photoreceptor layer was evident by histological examination of the eyes of RMG-vIL-10-treated animals ( Figure 7) . Interestingly, Figure 4 Intravitreal injection of Ad-vIL-10 protects rats against EAU. Groups of Lewis rats (four rats/group) were injected intravitreally in one eye with one of the following preparations: Ad-vIL-10, Ad-vIL-10mut (1 Â 10 9 pfu in 10 ml) and saline. These rats were immunized with S-Ag on the same day. Eyes were collected at day 21 postinjection, and EAU was scored histologically on a scale of 0-7. Scores obtained for both the injected eye (filled symbol) and the contralateral noninjected (corresponding open symbol) eyes are shown. The average score for each treatment group is shown by a horizontal bar. Rats were injected intravitreally with RMG-vIL-10 as described in the Materials and methods section. Eyes were collected at various time points after RMG-vIL-10 injection and isolated RNA was amplified with primers specific for vIL-10 or b-actin. cDNA products were electrophoresed on agarose gel. Data were obtained from one eye of one rat/group and are representative of two separate experiments.
Intraocular gene therapy for ocular inflammation C Verwaerde et al the protection was more evident in one hemiretina extending from the optic nerve to the periphery. No difference was observed between animals injected with saline or RMG-mut, indicating that the virus does not induce an immune response that could interfere with the S-Ag-specific immune response. In Experiment 1, detailed analysis showed that the protected surface of the outer nuclear layer of the retina represented 20.7% of the visual cell layer in RMG-vIL-10-treated rats (n¼5) compared to 0.06% in RMG-mut-treated rats (n¼3).
Delayed expression of vIL-10 protects against an ongoing EAU
In EAU, the autoimmune response is induced by systemic immunization, but the expression of the disease is organ-specific and occurs in the eye from 13 to 14 days. We thus investigated the effect of a delayed administration of RMG-vIL-10 on the outcome of EAU pathology. In a specific experiment (ie corresponding to Experiment 2), all rats were immunized with S-Ag, and then divided into two groups: one group of rats received RMG-vIL-10 or RMG-mut cells or saline on the same day of immunization, and the second group was injected with an identical cell inoculum (ie cells propagated from the same preparation and with the same passage number as in group one) on day 10, 3-4 days before the expected onset of the first observable clinical signs in controls, at a time when the immune response is already underway. Eyes were collected at day 16 of immunization for histological examination. As shown in Figure 5b , vIL-10 delivered by RMG-vIL-10 at day10 after immunization significantly protected the retina compared to the control RMG-mut group (22% reduction of EAU score), although less effectively than when antigen and RMG-vIL-10 were injected concomitantly (27% protection).
Administration of Mü ller cells expressing CTLA4-Ig protects against EAU
Recent literature has highlighted the possibility of limiting autoimmune process including uveitis by blocking the costimulatory molecule, CTLA4. [20] [21] [22] [23] [24] [25] We thus assessed whether our therapeutic approach, injecting genetically manipulated cells, was also effective for targeting CTLA4 into the eye. Intravitreal administration of RMG infected ex vivo with adenovirus expressing CTLA4-Ig fusion protein (RMG-CTLA4) led to comparable, and possibly even greater, protection against EAU than RMG-vIL-10 (29 and 39% of protection, respectively, for RMG-vIL-10 and RMG-CTLA4 compared to the control) ( Figure 6) . A very high level of CTLA4 was measured in the aqueous humor and the vitreous at day 4 after RMG-CTLA4 injection (5 mg/ml), corresponding to the elevated level of CTLA4 found in the supernatant of in vitro culture of RMG-CTLA4 (1.5 mg/24 h/3 Â 10 5 cells).
Intravitreal injection of vIL-10 or CTLA4 expressing RMG cells has no effect or very limited influence on the systemic anti-S-Ag immune response
After intravitreal injection of RMG-vIL-10, no vIL-10 was detectable in the sera of the treated animals by ELISA performed at day 4, 16 or 21 after inoculation (the limit of sensitivity of the ELISA for vIL-10 was approximately 2-5 pg/ml). To study the possible effect of vIL-10 on the development of the systemic autoimmune response, a DTH test was performed using S-Ag. No difference in ear swelling was observed between the different groups of rats (Experiment 2), either when RMG-vIL-10 was injected into the vitreous at day 0 (0.7570.12, 0.9370.10 and 0.8870.04 mm swelling for saline, RMG-mut and RMG-vIL-10, respectively) or at day 10 (0.8970.03 and 0.9970.14 mm for RMG-mut and RMG-vIL-10, respectively). In a T-cell lymphoproliferative assay performed on inguinal draining lymph node cells, no change in 3 Hthymidine uptake was observed in the RMG-vIL-10 group compared to the controls (Experiment 3, Figure  8a ). Finally, at the site of immunization (footpad of the animals), rats that received RMG-vIL-10 showed a comparable swelling due to granulomatous infiltration (3.3870.94 mm, n¼4) to RMG-mut (3.6270.47 mm, n¼4) or saline (3.2570.86 mm, n¼4)-injected controls (Experiment 1). These results indicated again that the protective effect observed in the eye was probably not due to a diminished systemic immune response.
In contrast to the absence of vIL-10 in the serum after RMG-vIL-10 injection, certainly due to the very strong local production of transgene by RMG-CTLA4, very low amounts of CTLA4 were detected in the sera of animals at day 4 (mean of 4 þ 1.6 ng/ml in the serum versus 5 mg/ ml in the vitreous), but not thereafter (days 7 and 21). This production could lead to some decrease in the immune response directed against S-Ag, as indicated by the decreased T-cell-specific proliferation compared to controls (Experiment 3) (Figure 8a) .
Finally, the humoral response directed against S-Ag and against the adenovirus was investigated in an additional experiment performed with RMG-vIL-10 and Ad-vIL-10mut (Figure 8b ). These last results indicated a clear difference between the effects of vIL-10 or CTLA4 produced by intravitreally injected RMG on the general versus the local immune responses. Indeed, intravitreal injection of transgene-expressing RMG had limited or no effect on the establishment of an immune response elicited systemically, whereas the immune response Figure 7 Photomicrographs showing histopathological changes in the eyes of rats with EAU. Rats were immunized with S-Ag. Eyes injected on the same day with RMG-vIL-10 (e, f), RMG-CTLA4 (g, h) and RMG-mut (c, d) (3 Â 10 5 cells/eye in 10 ml) were studied 21 days later. Normal retina is shown in (a, b). A low-magnification view of the posterior pole of the eye in the vicinity of the optic nerve is presented in (a, c, e, g), and a higher magnification in (b, d, f, h). In the RMG-mut-treated control group, there is complete destruction of the photoreceptor cell layer and destruction of part of the bipolar cell layer of the retina (c, d). In the RMG-vIL-10-treated (e, f) and RMG-CTLA4-treated (g, h) groups, there is preservation of the photoreceptor cell layer in areas situated on both sides of the pupilla of the optic nerve. The photoreceptor cells, including their outer segments, are indicated by a solid white arrow (v¼vitreous; r: retina; c: choroid; s: sclera; p: papilla, on: optic nerve, nerve fiber layer: nfl). Original magnification: (a, c, e, g): Â 40; (b, d, f, h): Â 250.
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Discussion
The eye is an organ that is highly suited to intraocular gene therapy. Numerous studies have demonstrated the efficiency of adenovirus-mediated transgene expression after intraocular injection into the vitreous body, the anterior chamber, the subretinal space and the periocular space. 26, 27 The potential for adenovirus-mediated gene transfer to treat ocular diseases has been explored in different pathological situations. Rescue and delay of photoreceptor cell death has been shown in rodent models of inherited eye disorders such as retinitis pigmentosa, using intraocular delivery of defective genes [28] [29] [30] or genes expressing neuroprotective molecules. [31] [32] [33] [34] In addition, the strategy of adenoviral-mediated gene transfer of immunomodulatory molecules has been successfully used to prolong survival of corneal allograft [34] [35] [36] [37] and to inhibit choroidal neovascularization. [38] [39] [40] Ocular inflammation may affect the eye in many ways and may be involved in many pathologies. Protection against experimental uveitis has been achieved by treatment with IL-10 of cellular or viral origin. 6,9,41 IL-10 is a pleiotropic cytokine that regulates numerous activities of hematopoietic cells, but its main functions are the regulation of inflammation by downregulating macrophage functions and by inhibiting the synthesis of proinflammatory cytokines and MHC class II molecule expression.
42, 43 We have previously shown that systemic production of vIL-10 delivered by i.v. or subconjunctival injection of recombinant adenovirus during mouse or rat EAU led to significant inhibition of pathological ocular manifestations. 9 Uveitis is a disease which mainly affects the posterior segment of the eye and is characterized by a breakdown of the blood-ocular barriers and an infiltration of activated inflammatory cells into the eye. These infiltrating cells are further stimulated by endogenous autoantigens presented locally, allowing ocular inflammation to proceed. Thus, inhibition of antigen presentation at the site of expression of the autoimmune disorders represents an attractive alternative to treat uveitis. We show here that injection of free Ad-GFP directly into the rat vitreous body results in high levels of gene expression in the different tissues of the eye, especially at the posterior pole, with Mü ller glial cells representing the largest population of infected cells. This work confirms previous observations. 44, 45 However, this method leads to a limited duration of gene expression, probably due to the rapid and intense immune response directed against the virus, characterized by the massive ED1 þ cell infiltration, as reported in other studies. 27, 46, 47 Nevertheless, injection of Ad-vIL-10 was found highly effective in prevention of EAU and the protection was limited to the Ad-vIL-10-injected eye, suggesting a local origin of its effect. However, infection of resident retinal cells and their subsequent destruction by the established immune response represents a major disadvantage of the method.
We thus decided to develop a strategy of injecting syngeneic ocular cells infected ex vivo into the vitreous body of a recipient. We focused our interest on retinal Mü ller glial (RMG) cells, which are giant cells spanning the full thickness of the retina from the internal to the external limiting membranes, their end feet lying along the internal limiting membrane in close contact with the vitreous and with the retinal blood vessels. RMG cells have been shown to express MHC class II in certain conditions and could be involved in local immune responses within the eye through local antigen presentation during uveitis. 48 Moreover, the choice of retinal cells to deliver molecules of interest to the posterior eye presents the advantage of injecting cells in an environment close to their natural location. In the present experiment, RMG showed a marked susceptibility to in vitro adenoviral infection and produced large quantities of cytokine, detectable in cellular supernatants. When RMG-GFP cells were injected into the vitreous, labeled cells were detected for up to 13 days in the vitreous, close to the posterior surface of the lens and often facing the papilla of the optic nerve. No reporter gene expression was detected in the recipient ocular tissues at any time postinjection. In three separate experiments involving RMG-vIL-10 transfer into the vitreous on the day of S-Ag immunization, significant preservation of the photoreceptor layer ranging from 27 to 29% was evident on histological examination. To evaluate the effect of the treatment on EAU, we estimated the extent of photoreceptor cell sparing, 9 without taking into account the inflammatory cell infiltration that could be attributed to the immune response to the viral and/or retinal autoantigens. The protection was more evident in one hemiretina from the optic nerve to the periphery. This localization could correspond to a diffusion of vIL-10 3 H-thymidine was added to the culture and the incorporation of radioactive product was analyzed 16 h later. Concanavalin A was used to control cell reactivity (results not shown). There were four animals in each group, corresponding to the experimental animals described in Figure 6 . (b) Sera were collected and antibodies directed against adenovirus and S-Ag were measured by ELISA. There were five animals in each group.
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C Verwaerde et al into the retina from RMG-vIL-10 cells that are located in the vitreous facing the papilla of the optic nerve, as observed using RMG-GFP cells. This protection was slightly less than that obtained by injecting virus directly into the vitreous, but had the advantages of using less virus (approximately 16-fold less) and of not infecting the resident visual cells of the recipient. The protection was achieved with an absence of detectable effect on the systemic immune response against the autoantigen, since there was no modification of the inflammation at the immunizing footpad site, and no effect on the specific DTH, the S-Ag T cell proliferation and anti-S-Ag antibody responses.
The efficiency of the strategy that we have developed, may originate from the inhibition of restimulation of autoantigen-specific lymphocytes infiltrating the eye. We investigated the effect of intravitreal RMG-vIL-10 treatment when the immune response is already underway, by injecting the cells 10 days after immunization, that is, 3-4 days before the expected onset of clinical signs. This delayed vIL-10 treatment showed comparable protection against the development of EAU, arguing in favor of a local effect of IL-10.
During our study, we also investigated retinal pigment epithelial (RPE) cells as possible cellular vehicle for vIL-10 expression. Compared to RMG cells, RPE cells showed similar sensitivity to adenovirus infection and comparable capacity to produce vIL-10 after Ad-vIL-10 infection. Nevertheless, no therapeutic effect was observed on EAU, certainly due to the rapid disappearance of RPE cells evidenced using Ad-GFP-infected RPE cells (data not shown). This result confirms our previous report showing that RPE cells do not survive when injected into the vitreous, 49 in contrast to observations of prolonged survival when cells are injected into the subretinal space, their usual intraocular environment. 31 In conclusion, our data demonstrated that IL-10 can exert its activity in vivo on an established autoimmune Tcell response and reduce lesions when expressed locally with in the eye.
To be effective, T-cell activation requires two signals. The first is initiated by T-cell receptor (TCR) recognition of a peptide-MHC complex, 50 and IL-10 exerts its inhibiting effect in part at this level, by downregulating the MHC II expression and thus the antigen presentation. The second is delivered by costimulatory signals, mainly by engagement of the B7 family of molecules on antigenpresenting cells, with their T-cell-associated ligands, CD28 and CTLA4.
51 CTLA4 has a much higher affinity for B7 molecules than CD28 and its engagement triggers a negative signal. 52, 53 Thus, it is a negative regulator of Tcell activation by blocking CD28-mediated signaling, and it has been considered as a potential tool for achieving therapeutical immunosuppression, particularly in autoimmune diseases, 54, 55 including experimental autoimmune anterior uveitis, 25 and in corneal allografts 34, 37, 56, 57 This protective effect was particularly marked when CTLA4 was expressed at the tissue site of the autoimmune disorders. 58, 59 In EAU, the CD28 pathway of costimulation is necessary to induce EAU, as systemic administration of antibodies to B7-1 and B7-2 during antigen challenge prevents the development of the disease and inhibits immunological responses. 8 We thus investigated the possibility of delivering CTLA4 by injection of genetically manipulated cells to inhibit EAU. Local expression of CTLA4 after intravitreal administration of RMG-CTLA4 inhibited the disease, more effectively than RMG-vIL-10 injection compared to controls (39% protection in RMG-CTLA4 treated rats versus 29% in RMG-vIL-10-treated rats), suggesting the importance of costimulatory molecules in the effector stage of EAU. Different recombinant CTLA4-expressing adenoviruses (described in the literature and including our construct) produce high levels of transgene in the serum after in vivo administration, even in the case of a local injection, for example, by the intra-articular route. 59 In our work, CTLA4 fusion protein was detected at high level (5 mg/ ml) in the vitreous, but it was not detected or was present at very low levels in the sera of animals. Thus, our approach provided efficient protection against the ocular disease, but avoided a profound inhibition of host immune response which is clearly necessary to face other infections. It is difficult to know whether the difference in the level of protection observed between RMG-vIL-10 and RMG-CTLA4 resulted from an effect on different targets or was due to the difference in the amount of molecule produced locally. Nevertheless, due to its capacity to block costimulatory signals, CTLA4 is considered as a potent inhibitor of antigen presentation, whereas IL-10 may act primarily as a regulatory molecule of antigen presentation by decreasing MHC II molecules. Interestingly, preliminary results indicated that some increase in protection could be obtained by coexpressing the two factors into the eye (data not shown). The study of this additive effect is now under investigation.
Numerous studies have reported the ability of retinal cells to produce factors of interest after in vitro recombinant adenoviral infection or following in vivo infection of these cells after intraocular injection of the virus. [60] [61] [62] [63] However, to our knowledge, this is the first work that reports successful treatment of experimental uveitis after transplantation of ex vivo genetically modified retinal cells. Our work highlights a growing interest in local gene therapy using factors that modify the local cytokine milieu and downregulate antigen presentation in organ-specific autoimmune diseases.
Material and methods
Animals
Male Lewis rats used in this study were between 8 and 11 weeks of age (Charles Rivers, Saint-Aubin-lès-Elbeuf, France). All animals were cared for in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Cells
RMG cells (passage 2-3) were established as previously described. 64 Briefly, eyeballs taken from decerebrated Lewis rats at postnatal day 8-12 were incubated in DMEM (Gibco, Grand Island, NY, USA) containing 0.2% trypsin (Difco, Detroit, MI, USA) and 100 U/ml collagenase (Worthington, Freehold, NJ, USA) at 371C. The neural retinas were separated from the lens and vitreous, cut into small fragments and plated in 100 mm petri dishes in DMEM containing 10% FCS (Gibco). After 3-4 days, fragments were removed by extensive rinsing with Intraocular gene therapy for ocular inflammation C Verwaerde et al PBS. Cells grew rapidly, and cultures were further expanded by trypsination and reseeding into 100 mm dishes prior to seeding into plates for assay purposes.
To establish the purity of rat RMG, cells grown on coverslips were processed for immunocytochemical studies. 64 For Mü ller cell phenotype determination, cytoskeletal markers and myoid-type actin cytoskeleton were characterized in vitro in adenovirus-infected RMG and in vivo after injection of infected RMG cells into the eyes. Cryostat-cut sections of ocular globes injected with free Ad-GFP or with RMG-GFP were stained with the following antibodies: CRALBP (gift from Dr John Saari, University of Washington School of Medicine, Seattle, WA, USA), rabbit polyclonal antiglial fibrillary acidic protein (GFAP, Dakopatts, Trappes, France), mouse monoclonal antivimentin (VIM, Sigma, St Louis, MO, USA), a marker of one of the five groups of cytoskeletal cytokeratin (CytoK; Boehringer-Mannheim, Mannheim, Germany), monoclonal OX42 (Serotec, Oxford, UK) (antiC3b antigen and a marker for macrophage subsets including microglia) and mouse monoclonal anti-a smooth muscle actin (clone 1A4; Sigma), a marker expressed in myofibroblasts described in contracting granulation tissue. 19 To visualize the inflammatory reaction in injected eyes, the monoclonal ED1 þ antibody (Serotec), a marker for monocytes, macrophages and some dendritic cell populations were used.
Recombinant adenovirus constructs
Construction of the replicative defective adenoviral vector expressing vIL-10 (Ad-vIL-10) and adenoviral vector expressing mutated IL-10 (Ad-vIL-10mut) was described previously. 65 Briefly, the BCRF1-coding gene (À16, þ 625), flanked in 5 0 with the promoter of the cytomegalovirus and in 3 0 with a SV40 polyadenylation sequence, was inserted in E1 region into the adenoviral genome. In the Ad-vIL-10mut control, a mutation was inserted in position þ 71, just after the signal sequence, leading to a modification of the reading frame. Ad-CTLA4 (expressing mouse CTLA4-human IgG1 fusion protein driven by RSV promoter) was described previously. 30 Ad-GFP (promoter: CMV) was a generous gift of Dr M Methali (Transgène, Strasbourg, France).
In vitro adenovirus cell infection
RMG (2-3 passages, 80% confluence) was infected with adenovirus at various ratios of plaque-forming unit (pfu)/cell in OptiMEM medium (Gibco) in the absence of FCS at 371C. After 1 h, medium was replaced with OptiMEM, 2%FCS and incubated at 371C, 5%CO 2 until use.
For vIL-10 or CTLA4 production analysis, 0.5 ml supernatants were collected every day for 6 days and stored at À801C before determination by ELISA as described previously. 34, 65 In the case of Ad-GFP infection, the expression of transgene was controlled by direct microscopic observation of the cell layer under UV light.
For FACS analysis or in vivo delivery, cells were collected either by scrapping or EDTA-trypsin treatment and washed in cold PBS prior to use. For in vivo experiments, cells were infected with adenovirus vectors at 200 pfu/cell ratio, 1 day before their injection into the eyes of animals.
Induction of EAU
S-Antigen (S-Ag) was purified from bovine retinas. 3 The antigen was emulsified (1:1) in complete Freund's adjuvant (CFA, Difco, Detroit, MI, USA), supplemented with 250 mg of Mycobacterium tuberculosis H37Ra (Difco). A total of 0.2 ml containing 30 mg of S-Ag was injected into the footpads of each rat.
Treatment of EAU
Prior to intravitreal injection, rats were anesthetized and the pupil was dilated. Intravitreal injection of virus (1 Â 10 9 pfu/eye in 10 ml) or infected cells (3 Â 10 5 cells/eye in 10 ml) was monitored under an operating microscope using a sterile syringe with a 29G needle (Micro-fine, Becton Dickinson, Meylan, France). Any bleeding or lens touch observed at the end of the injection excluded the rat from the protocol. Selected animals were then immunized with S-Ag in order to induce EAU.
Ocular histopathological examination
Rat eyes were enucleated 16-21 days after immunization. For histological analysis and EAU grading, the material was fixed for 24 h in Bouin's solution, paraffin-embedded and sections were made through the pupillary-optic nerve plane and stained with hematoxylin-eosin. The incidence and severity of EAU were scored by a masked investigator on a semiquantitative scale of 0 to 7:
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: 0, no destruction, no cell infiltration, 1-7, limited or total destruction of the various layers of the retina: grades 1-2: destruction of outer segments of rods and cones, grades 3-4: destruction of the outer nuclear layer, grades 5-6: of the inner nuclear layer and grade 7: destruction of the ganglion cell layer. Severity of disease was calculated as the mean value for all rats from three separate experiments. From these values, the level of protection was also expressed as: percentage protection¼(EAU grade in Ad-vIL-10mut animals minus EAU grade in Ad-vIL-10-treated animals)/EAU grade in AdvIL-10mut animals.
In some experiments, the degree of Ad-vIL-10 protection was further quantified by measuring the outer nuclear layer (ONL) surface, which served as an index of photoreceptor loss or protection as previously described. 9 The ONL surface of rats injected with Ad-vIL-10 or Ad-vIL-10mut was measured and a percentage of protection was calculated for each rat, as compared with the surface value of normal controls. 9 For GFP expression determination, the ocular globes were fixed in 2% paraformaldehyde for 4 h at RT and after washing with PBS, were embedded in OCT (Tissuetek, Miles, Elkhart, IN) and snap frozen in liquid isopentane as previously described. 9 Transgene expression was characterized on 10 mm sections under UV light for GFP.
ED1 and GFAP determinations were determined as previouly described. 67 Briefly, sections were incubated with mouse monoclonal antibody anti-ED1 (Serotec, Oxford, UK, diluted 1:50), or with rabbit polyclonal anti-GFAP (Dakopatts, Trappes, France, diluted 1:100), then incubated, respectively, with Texas red-conjugated donkey anti-mouse IgG or with Texas red-conjugated 
Immune response estimation
The effect of Ad-vIL-10 treatment on the immune response was evaluated by different approaches. 9 First, as a global analysis, rats were examined for the footpad reactivity, site of the S-Ag immunization and a score was given from 0 to 3. Briefly, the scoring was as follows: indurations and redness¼1; edema and swelling¼2; necrosis¼3. Second, the specific anti-S-Ag response was estimated by specific delayed type hypersensitivity (DTH), using a skin test performed at the ear. 9 Immunoreactivity was also assessed by measuring the 3 H-thymidine incorporation by Ag-stimulated T cells from inguinal lymph nodes as previously described. 67 Finally, in some experiments, the antibody responses directed against S-Ag and adenovirus were analyzed.
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Analysis of vIL-10 and CTLA4 expression For vIL-10 and CTLA4 RT-PCR studies, eyes were rapidly frozen in liquid nitrogen and kept at À801C until the time of the experiment. RT-PCR was performed from RNA isolated by the acid guanidium thiocyanatephenol-chloroform method using a couple of primers that recognized specifically the viral cytokine (vIL10 sense: 5 0 -ATGGAGCGAAGGTTAGTGGTC-3 0 ; vIL-10 antisense: 5 0 -ACTCTTGTTCTCACACGGCAG-3 0 ; 455 bp product), or CTLA4 (CTLA4 sense: 5 0 -GAGGTCCGGGT GACTGTGCTGCGG, CTLA4 antisense: 5 0 CTGCGTCC CGTTGCCCATGCCCAC, 242 bp product) as described. The PCR fragments were analyzed by agarose gel electrophoresis and vizualized by ethidium bromide staining. vIL-10 and CTLA4 protein determinations were performed by ELISA as previously described, either on pooled samples of aqueous humor (from both eyes of five animals), or individually on serum specimens.
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FACS analysis
After 24 or 48 h incubation, Ad-GFP-infected cells were recovered by EDTA-trypsin treatment, washed two times with cold PBS and then fixed 10 mn at RT with 4% paraformaldehyde. Flow cytometry analysis was performed using a EPICS II cytometer (COULTER, Hialeah, FL, USA) at 10 000 events per sample.
Statistical analysis
Data are presented as mean7s.e.m. Statistical analysis of EAU scoring was performed using the nonparametric Mann-Whitney sum test or by the Kruskal-Wallis nonparametric ANOVA test, followed by the Bonferroni multiple comparison test. A P-value adjusted by the multiple comparison test was calculated in each experiment. Values of Po0.05 were considered significant.
